Evaxion Biotech A/S ADR (EVAX)

$1.66 +0.02 (1.22%)
Market Cap 2.30M
Revenue (ttm) 3.34M
Net Income (ttm) -10.57M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -316.47%
Debt to Equity Ratio -4.95
Volume 57,600
Avg Vol 68,002
Day's Range N/A - N/A
Shares Out 1.40M
Stochastic %K 76%
Beta -0.24
Analysts Strong Sell
Price Target $13.25

Company Profile

Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based cancer vaccine that has completed Phase 1/2a trial to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers, including non-small...

Industry: Biotechnology
Sector: Healthcare
Phone: 45 31 31 97 53
Website: evaxion.ai
Address:
Dr. Neergaards Vej, 5th Floor, Horsholm, Denmark
TradingLaboratory
TradingLaboratory Jul. 5 at 1:26 AM
$EVAX proof of concept study sounds good
0 · Reply
Manwiththeplan
Manwiththeplan Jul. 2 at 7:37 PM
$EVAX it is weird that the CSO replaces Kanstrup. She does not have a commercial background. Or kanstrup did something stupid or it is a coming partnership
1 · Reply
Manwiththeplan
Manwiththeplan Jul. 2 at 7:26 PM
$EVAX Chat GPT: > Based on the timing of Christian Kanstrup’s departure, the language in Evaxion’s official announcement, and the company’s current strategic and financial context, there is a realistic probability (estimated at 60–75%) that Evaxion will announce a licensing deal or strategic partnership within the next 3 to 6 months
0 · Reply
Tigerz11
Tigerz11 Jul. 2 at 6:32 AM
$EVAX
0 · Reply
TradeHawk
TradeHawk Jul. 1 at 6:20 PM
$EVAX The Vaccine journal has a publication out today describing a proof-of-concept study, using Evaxion's AI-immunology platform, about identification of a Pseudomonas aeruginosa vaccine which improved outcomes in a murine biofilm lung infection model. https://www.sciencedirect.com/science/article/pii/S0264410X25007133
0 · Reply
Manwiththeplan
Manwiththeplan Jul. 1 at 5:07 PM
$EVAX weird news. I hope it has to do with a partership or buyout
0 · Reply
Lenni_D
Lenni_D Jul. 1 at 12:59 PM
$EVAX https://investors.evaxion.ai/news-releases/news-release-details/evaxion-announces-changes-executive-management-optimize-value Good news. Horrible CEO is out. 14 m revenue for 2024 turned into 3 m. And nothing in 2025 yet.
0 · Reply
Manwiththeplan
Manwiththeplan Jun. 25 at 7:06 PM
$EVAX the best thing is that the company is achieving the milestones this year. Looking forward to Q3. Very bullish
0 · Reply
YouVSYou
YouVSYou Jun. 25 at 6:29 PM
$EVAX 2.41 ww
0 · Reply
ZacksSCR
ZacksSCR Jun. 25 at 4:06 PM
$EVAX AI Technology Produces New Vaccine Candidate https://buff.ly/lLUobNP
0 · Reply
Latest News on EVAX
Evaxion announces changes to Executive Management to optimize the value of proprietary AI-Immunology™ platform and portfolio

Jul 1, 2025, 8:30 AM EDT - 5 days ago

Evaxion announces changes to Executive Management to optimize the value of proprietary AI-Immunology™ platform and portfolio

Evaxion expands R&D pipeline with new vaccine program targeting Group A Streptococcus

Jun 25, 2025, 8:00 AM EDT - 11 days ago

Evaxion expands R&D pipeline with new vaccine program targeting Group A Streptococcus

Evaxion receives grant funding to design new polio vaccine

Jun 3, 2025, 9:15 AM EDT - 4 weeks ago

Evaxion receives grant funding to design new polio vaccine

Evaxion Biotech A/S (EVAX) Q1 2025 Earnings Conference Call Transcript

May 27, 2025, 10:43 AM EDT - 5 weeks ago

Evaxion Biotech A/S (EVAX) Q1 2025 Earnings Conference Call Transcript

Evaxion announces business update and first quarter 2025 financial results

May 27, 2025, 7:30 AM EDT - 5 weeks ago

Evaxion announces business update and first quarter 2025 financial results

Evaxion: Progress Unrecognized By Market And A Catalyst-Full 2025

May 26, 2025, 8:47 AM EDT - 5 weeks ago

Evaxion: Progress Unrecognized By Market And A Catalyst-Full 2025

Evaxion to announce business update and first quarter 2025 financial results on May 27, 2025

May 23, 2025, 8:00 AM EDT - 6 weeks ago

Evaxion to announce business update and first quarter 2025 financial results on May 27, 2025

Evaxion doses first patient in extension of phase 2 trial exploring the full potential of AI-designed personalized cancer vaccine EVX-01

May 22, 2025, 8:00 AM EDT - 6 weeks ago

Evaxion doses first patient in extension of phase 2 trial exploring the full potential of AI-designed personalized cancer vaccine EVX-01

80% of the EVX-01 vaccine targets trigger a tumor-reactive immune response - Evaxion presents striking EVX-01 data at the AACR Annual meeting

Apr 28, 2025, 8:00 AM EDT - 2 months ago

80% of the EVX-01 vaccine targets trigger a tumor-reactive immune response - Evaxion presents striking EVX-01 data at the AACR Annual meeting

Evaxion to present at World Vaccine Congress

Apr 10, 2025, 8:00 AM EDT - 3 months ago

Evaxion to present at World Vaccine Congress

Evaxion Biotech A/S (EVAX) Q4 2024 Earnings Call Transcript

Apr 1, 2025, 11:21 AM EDT - 3 months ago

Evaxion Biotech A/S (EVAX) Q4 2024 Earnings Call Transcript

Evaxion to announce business update and full year 2024 financial results on April 1, 2025

Mar 27, 2025, 8:00 AM EDT - 3 months ago

Evaxion to announce business update and full year 2024 financial results on April 1, 2025

Evaxion to present new phase 2 data for AI-designed personalized cancer vaccine EVX-01 at AACR Annual Meeting

Mar 25, 2025, 4:30 PM EDT - 3 months ago

Evaxion to present new phase 2 data for AI-designed personalized cancer vaccine EVX-01 at AACR Annual Meeting

Evaxion extends phase 2 trial with personalized cancer vaccine EVX-01 to further enhance clinical data package

Feb 25, 2025, 8:00 AM EST - 4 months ago

Evaxion extends phase 2 trial with personalized cancer vaccine EVX-01 to further enhance clinical data package

Evaxion announces closing of $10.8 million public offering

Jan 31, 2025, 4:05 PM EST - 5 months ago

Evaxion announces closing of $10.8 million public offering

Evaxion announces pricing of $10.8 million public offering

Jan 30, 2025, 8:00 AM EST - 5 months ago

Evaxion announces pricing of $10.8 million public offering

Evaxion granted 180-day compliance extension by Nasdaq as it restores equity above minimum requirement

Jan 28, 2025, 8:15 AM EST - 5 months ago

Evaxion granted 180-day compliance extension by Nasdaq as it restores equity above minimum requirement

Evaxion announces completion of ADS ratio change

Jan 14, 2025, 4:05 PM EST - 6 months ago

Evaxion announces completion of ADS ratio change

Evaxion announces extension to January 14, 2025, of plan to implement ADS ratio change

Jan 10, 2025, 8:00 AM EST - 6 months ago

Evaxion announces extension to January 14, 2025, of plan to implement ADS ratio change

Evaxion announces plan to implement ADS ratio change

Dec 30, 2024, 8:00 AM EST - 6 months ago

Evaxion announces plan to implement ADS ratio change

Evaxion announces positive preclinical data for cytomegalovirus (CMV) vaccine program EVX-V1

Nov 12, 2024, 8:00 AM EST - 8 months ago

Evaxion announces positive preclinical data for cytomegalovirus (CMV) vaccine program EVX-V1

Evaxion announces business update and third quarter 2024 financial results

Oct 31, 2024, 8:00 AM EDT - 8 months ago

Evaxion announces business update and third quarter 2024 financial results

Evaxion to announce business update and third quarter 2024 financial results on October 31

Oct 28, 2024, 8:00 AM EDT - 8 months ago

Evaxion to announce business update and third quarter 2024 financial results on October 31

Strong validation of Evaxion's AI-Immunology™ platform in multiple clinical trials

Oct 9, 2024, 8:00 AM EDT - 9 months ago

Strong validation of Evaxion's AI-Immunology™ platform in multiple clinical trials

Recent clinical data confirms significantly improved predictive power of Evaxion's AI-Immunology™ platform

Oct 3, 2024, 8:00 AM EDT - 9 months ago

Recent clinical data confirms significantly improved predictive power of Evaxion's AI-Immunology™ platform

Evaxion Biotech Partners With Merck To Expand Vaccine Development

Sep 26, 2024, 10:53 AM EDT - 10 months ago

Evaxion Biotech Partners With Merck To Expand Vaccine Development

MRK

Evaxion significantly expands vaccine development collaboration with MSD

Sep 26, 2024, 7:30 AM EDT - 10 months ago

Evaxion significantly expands vaccine development collaboration with MSD

Evaxion launches improved AI-Immunology™ platform for vaccine antigen prediction

Sep 19, 2024, 8:00 AM EDT - 10 months ago

Evaxion launches improved AI-Immunology™ platform for vaccine antigen prediction

Evaxion obtains pre-clinical Proof-of-Concept for mRNA Gonorrhea vaccine candidate EVX-B2

Sep 9, 2024, 7:00 AM EDT - 10 months ago

Evaxion obtains pre-clinical Proof-of-Concept for mRNA Gonorrhea vaccine candidate EVX-B2

Evaxion Biotech A/S (EVAX) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 11:43 AM EDT - 11 months ago

Evaxion Biotech A/S (EVAX) Q2 2024 Earnings Call Transcript

Evaxion to Announce Business Update and Second Quarter 2024 Financial Results on August 14

Aug 12, 2024, 7:27 AM EDT - 11 months ago

Evaxion to Announce Business Update and Second Quarter 2024 Financial Results on August 14

Evaxion to Present One-Year Clinical Efficacy Data from its Phase 2 Study on Lead Cancer Vaccine Candidate, EVX-01, at the ESMO Congress 2024 in September

Aug 8, 2024, 8:00 AM EDT - 11 months ago

Evaxion to Present One-Year Clinical Efficacy Data from its Phase 2 Study on Lead Cancer Vaccine Candidate, EVX-01, at the ESMO Congress 2024 in September

Evaxion Showcases Improved Performance of Key Building Block in AI-Immunology™ at Computational Biology Conference

Jul 16, 2024, 7:30 AM EDT - 1 year ago

Evaxion Showcases Improved Performance of Key Building Block in AI-Immunology™ at Computational Biology Conference

Evaxion Reinforces Milestone Timeline and Provides Shareholder Update

Jul 3, 2024, 8:05 AM EDT - 1 year ago

Evaxion Reinforces Milestone Timeline and Provides Shareholder Update

Evaxion Receives Positive Feedback on Patent Application for AI-Based Novel Cancer Vaccine Target Identification Method

Jun 26, 2024, 7:30 AM EDT - 1 year ago

Evaxion Receives Positive Feedback on Patent Application for AI-Based Novel Cancer Vaccine Target Identification Method

Evaxion Publishes Data, Showing 67% Objective Response Rate in Metastatic Melanoma for the AI-Designed Personalized Cancer Vaccine EVX-01, in Leading Medical Journal

Jun 17, 2024, 8:44 AM EDT - 1 year ago

Evaxion Publishes Data, Showing 67% Objective Response Rate in Metastatic Melanoma for the AI-Designed Personalized Cancer Vaccine EVX-01, in Leading Medical Journal

Evaxion Presents Positive and Validating Immune Data from Ongoing Phase 2 Trial with AI-Designed EVX-01 Vaccine at the ASCO Annual Meeting 2024

Jun 3, 2024, 8:00 AM EDT - 1 year ago

Evaxion Presents Positive and Validating Immune Data from Ongoing Phase 2 Trial with AI-Designed EVX-01 Vaccine at the ASCO Annual Meeting 2024

Evaxion Announces Business Update and First Quarter 2024 Financial Results

May 28, 2024, 8:21 AM EDT - 1 year ago

Evaxion Announces Business Update and First Quarter 2024 Financial Results

Evaxion to Present New Positive Data from Ongoing Phase 2 Study on Lead Vaccine Candidate EVX-01 at the American Society of Clinical Oncology Annual Meeting 2024

May 23, 2024, 5:00 PM EDT - 1 year ago

Evaxion to Present New Positive Data from Ongoing Phase 2 Study on Lead Vaccine Candidate EVX-01 at the American Society of Clinical Oncology Annual Meeting 2024

Evaxion Receives Nasdaq Notification

May 10, 2024, 5:00 PM EDT - 1 year ago

Evaxion Receives Nasdaq Notification

Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01

Apr 17, 2024, 8:00 AM EDT - 1 year ago

Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01

Evaxion Biotech A/S (EVAX) Q4 2023 Earnings Call Transcript

Apr 2, 2024, 2:10 PM EDT - 1 year ago

Evaxion Biotech A/S (EVAX) Q4 2023 Earnings Call Transcript

Evaxion and Undisclosed Collaborator Announce Encouraging Results for EVX-B1 Vaccine Antigens Against Staphylococcus Aureus Infection

Apr 2, 2024, 7:00 AM EDT - 1 year ago

Evaxion and Undisclosed Collaborator Announce Encouraging Results for EVX-B1 Vaccine Antigens Against Staphylococcus Aureus Infection

Evaxion Announces Business Update and Full Year 2023 Financial Results

Mar 27, 2024, 7:30 AM EDT - 1 year ago

Evaxion Announces Business Update and Full Year 2023 Financial Results

Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology™ Platform

Mar 19, 2024, 7:30 AM EDT - 1 year ago

Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology™ Platform

Evaxion to Host R&D Day on March 19, 2024, Highlighting its Latest Technology Innovations

Feb 29, 2024, 7:30 AM EST - 1 year ago

Evaxion to Host R&D Day on March 19, 2024, Highlighting its Latest Technology Innovations

Evaxion Announces Successful Completion of the Initial Phases of Ongoing Vaccine Collaboration with MSD

Feb 20, 2024, 7:30 AM EST - 1 year ago

Evaxion Announces Successful Completion of the Initial Phases of Ongoing Vaccine Collaboration with MSD

Evaxion Regains Compliance with Nasdaq Minimum Bid Price Requirement

Feb 7, 2024, 8:30 AM EST - 1 year ago

Evaxion Regains Compliance with Nasdaq Minimum Bid Price Requirement

Evaxion Announces Closing of $15 Million Public Offering

Feb 6, 2024, 8:30 AM EST - 1 year ago

Evaxion Announces Closing of $15 Million Public Offering

Evaxion Biotech Announces Pricing of $15 Million Public Offering

Feb 1, 2024, 9:20 AM EST - 1 year ago

Evaxion Biotech Announces Pricing of $15 Million Public Offering

TradingLaboratory
TradingLaboratory Jul. 5 at 1:26 AM
$EVAX proof of concept study sounds good
0 · Reply
Manwiththeplan
Manwiththeplan Jul. 2 at 7:37 PM
$EVAX it is weird that the CSO replaces Kanstrup. She does not have a commercial background. Or kanstrup did something stupid or it is a coming partnership
1 · Reply
Manwiththeplan
Manwiththeplan Jul. 2 at 7:26 PM
$EVAX Chat GPT: > Based on the timing of Christian Kanstrup’s departure, the language in Evaxion’s official announcement, and the company’s current strategic and financial context, there is a realistic probability (estimated at 60–75%) that Evaxion will announce a licensing deal or strategic partnership within the next 3 to 6 months
0 · Reply
Tigerz11
Tigerz11 Jul. 2 at 6:32 AM
$EVAX
0 · Reply
TradeHawk
TradeHawk Jul. 1 at 6:20 PM
$EVAX The Vaccine journal has a publication out today describing a proof-of-concept study, using Evaxion's AI-immunology platform, about identification of a Pseudomonas aeruginosa vaccine which improved outcomes in a murine biofilm lung infection model. https://www.sciencedirect.com/science/article/pii/S0264410X25007133
0 · Reply
Manwiththeplan
Manwiththeplan Jul. 1 at 5:07 PM
$EVAX weird news. I hope it has to do with a partership or buyout
0 · Reply
Lenni_D
Lenni_D Jul. 1 at 12:59 PM
$EVAX https://investors.evaxion.ai/news-releases/news-release-details/evaxion-announces-changes-executive-management-optimize-value Good news. Horrible CEO is out. 14 m revenue for 2024 turned into 3 m. And nothing in 2025 yet.
0 · Reply
Manwiththeplan
Manwiththeplan Jun. 25 at 7:06 PM
$EVAX the best thing is that the company is achieving the milestones this year. Looking forward to Q3. Very bullish
0 · Reply
YouVSYou
YouVSYou Jun. 25 at 6:29 PM
$EVAX 2.41 ww
0 · Reply
ZacksSCR
ZacksSCR Jun. 25 at 4:06 PM
$EVAX AI Technology Produces New Vaccine Candidate https://buff.ly/lLUobNP
0 · Reply
Manwiththeplan
Manwiththeplan Jun. 25 at 12:31 PM
$EVAX nice this was the last milestone for h1. Nice work
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Jun. 25 at 12:22 PM
$EVAX Evaxion Initiates Work To Develop New Preventive Vaccine Against Group A Streptococcus; New Vaccine Program Added To Evaxion's Pipeline Under Name EVX-B4
0 · Reply
Stmkr
Stmkr Jun. 25 at 12:09 PM
$EVAX Very interesting addition to the pipeline. I like it. Partnership coming there soon
0 · Reply
Lenni_D
Lenni_D Jun. 25 at 12:09 PM
$EVAX Evaxion expands R&D pipeline with new vaccine program targeting Group A Streptococcus https://investors.evaxion.ai/news-releases/news-release-details/evaxion-expands-rd-pipeline-new-vaccine-program-targeting-group
0 · Reply
Manwiththeplan
Manwiththeplan Jun. 24 at 5:24 PM
$EVAX https://www.linkedin.com/posts/evaxion-biotech_we-are-excited-to-announce-our-participation-activity-7341427545923276800-pWDo?utm_source=share&utm_medium=member_android&rcm=ACoAABExqvoBWwzDD6xigEZBHiFGbOfmK15eFqs
0 · Reply
Manwiththeplan
Manwiththeplan Jun. 20 at 6:20 PM
$EVAX 3 in july, 4 in august, 9 in september.
1 · Reply
Manwiththeplan
Manwiththeplan Jun. 18 at 6:25 PM
$EVAX strange price action here
0 · Reply
PharmaExpert
PharmaExpert Jun. 18 at 3:15 PM
$AKBA, $APVO, $GOVX, $TRVN, $EVAX 🔥🔥🔥🔥🔥
2 · Reply
Stmkr
Stmkr Jun. 18 at 4:48 AM
$AZTR $QNRX AZTR ✓ Next favorites; - $QNRX - $EVAX
0 · Reply
Manwiththeplan
Manwiththeplan Jun. 17 at 5:10 PM
$EVAX good opportunity to buy more
0 · Reply
TarrynItUp
TarrynItUp Jun. 10 at 4:35 PM
$EVAX my average is still sitting at $6.02. I’m liking where this I headed
1 · Reply
Tigerz11
Tigerz11 Jun. 9 at 6:03 PM
$EVAX runway paving
0 · Reply